The story does a solid job of explaining that the current research, a Phase I study, can establish only that the procedure is safe, not that it is effective. The reader learns about the differences among the three phases of studies the FDA requires. The reader learns about how stem cells might benefit damaged heart muscle.
Having said that, this story raises an existential question: Should the story have been done?
If the results can prove only safety but not efficacy, why should a reader care? A story that demonstrates safety of a technique of no known benefit would never see mainstream publication.
But the Phase I study results does show some promising benefits, and related research provides reason to believe the technique may indeed be useful. So should CNN report the story because of those apparent benefits, despite their not being established by data?
That’s a lot of worry about one story. CNN decided to run with it. The report adds responsible context. The reader ultimately gets a mostly fair-minded report on promising early research into a new kind of stem cell research for heart disease. No reader would expect that the treatment is available or imminent.
At the end of the day, that’s not a bad outcome.
Despite advances in diagnostics and therapies, heart attack and its consequences represent a significant problem. This report highlights the results of an early phase 1 trial comparing a placebo infusion to an infusion of processed adult stem cells in patients with recent first heart attacks. The approach holds the potential to repair damage caused by a heart attack making subsequent heart failure less likely.
The story reports that harvesting enough stem cells for infusion is difficult and costly, though it fails to cite specific costs.
For research in Phase I, any comment on cost might be purely speculative.
Since the study is designed to prove safety, there are no credible benefits data to report.
The report does allow sources to make general claims of benefit based on that preliminary data, but the reporter shows restraint by not plucking benefits data points from the study.
On a close call, the story earns a satisfactory rating.
While the story briefly mentions the potential for rejection, it fails otherwise to specify the potential side effects of the stem cell harvesting or infusion. This is surprising, given the fact that the Phase I trial is designed to prove safety.
The story makes plain that the evidence from the published study can only prove safety, not efficacy. It does a good job educating readers about the three phases of FDA trials and what each is designed to establish.
The story does nothing to exaggerate the prevalence or severity of the damage to the heart muscle by heart attacks.
The story uses two sources: One stem cell expert who is not involved with the research, and the lead author of the published paper.
While that’s thin sourcing for a story of this length, it’s sufficient to earn a satisfactory rating.
The story compares this process, which involves infusing the patient with a donor’s bone marrow stem cells, with both use of the patient’s own stem cells and with surgical introduction of the cells.
The story does not specify conventional treatments for heart failure, which would have provided useful context. Still, the story earns a satsifactory rating.
Most of the story makes it clear that the technique is in early trials and not in clinical use. Only the opening line is troubling – "If you’ve just had your first heart attack, doctors may one day be able to reverse the damage done with stem cell therapy." Due to clumsy wording, this suggests that if you had your first heart attack in late 2009, doctors may someday be able to reverse today’s damage from it – which is not at all the case.
But this misstep is remedied by a later statement that it would take a best-case scenario to have such an approach approved even in five years.
The story does not make false claims for the procedure’s novelty. See he criterion – "Compare the new approach with existing alternatives" – below.
There’s no evidence that the story relied on a news release.
Systematic, Criteria-Driven
Like Michael Corleone of science reporting that @garyschwitzer is (he tries to get out, bullshit disguised as #science #journalism keeps pulling him back in!), he drops this on @nytimes idiocy 🙄 in reporting T1 diabetes "cure"
HT @HealthNewsRevu
https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
"But it is the framing and the emphasis of the #journalism by a leading science journalist at a leading newspaper that demands scrutiny. It has an impact on readers and on sick people that may cause harm by promoting false hope about extremely preliminary research"
👍👏💪 truth https://twitter.com/garyschwitzer/status/1465399358137024518
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like